Trastuzumab Combined to Neoadjuvant Chemotherapy in Patients With HER2-Positive Breast Cancer
Neoadjuvant Chemotherapy Plus Trastuzumab in HER2+ Breast Cancer
A Valachis, D Mauri, NP Polyzos, G Chlouverakis, D Mavroudis, V Georgoulias
Yes
20111101
2011 Dec 1
Breast
Trastuzumab Combined to Neoadjuvant Chemotherapy in Patients With HER2-Positive Breast Cancer
Breast. 2011 Dec 1;20(6):485-490, A Valachis, D Mauri, NP Polyzos, G Chlouverakis, D Mavroudis, V Georgoulias
Abstract
Abstract
Purpose: To perform a meta-analysis in order to quantify the actual cumulative randomized evidence for the benefit and toxicity of trastuzumab combined with neoadjuvant chemotherapy in HER2-positive breast cancer.Methods: Potentially eligible trials were located through PubMed and Cochrane Library searches and abstracts of major international conferences. The endpoints that we assessed were pathologic complete response (pCR) rate, breast-conserving surgery (BCS) rate and toxicity.Results: Five trials...
